EVT Evotec SE

XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · evotec.com

2.962EUR+1.44%Mkt Cap: 572.10M $P/E: —Today

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biolog…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Zoetis Inc. Class A Common Stock

$28.80BUSDP/E 11.4

UTHR

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB

$14.24BUSDP/E 109.4

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap572.10M USD

Enterprise Value575.09M USD

Revenue (TTM)779.66M USD

Gross Profit124.15M USD

Net Income (TTM)-112.52M USD

Revenue/Share4.04 EUR

Last Price2.962 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees4.5K

CountryDE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-6.99

PEG1.43

EV/EBITDA-7.23

EV/Revenue0.74

P/S0.72

P/B0.78

EPS (TTM)-1.10

EPS (Forward)-0.42

52W Range

2.7105% of range7.300

52W High7.300 EUR

52W Low2.710 EUR

Profitability

Gross Margin14.49%

Oper. Margin-62.26%

EBITDA Margin-10.20%

Profit Margin-13.13%

ROE-12.72%

ROA-6.04%

Growth

Revenue Growth-16.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-9.98M USD

CapEx (TTM)89.81M USD

FCF Margin-11.29%

FCF Yield-15.39%

Net Debt11.17M USD

Net Debt/EBITDA-0.14

Balance Sheet

Debt/Equity0.55

Current Ratio2.33

Quick Ratio2.02

Book Value/Sh3.75 EUR

Cash/Share2.62 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split2:1

Split DateAug 18, 2000

Analyst Consensus

Rating2.6 (Hold)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)4.586 EUR

Upside (mean)+54.8%

Target Range3.500 EUR – 10.00 EUR

3.500+54.8% to mean10.00

# Analysts7

Ownership

Shares Out.177.69M

Float135.49M

Insiders9.97%

Institutions62.11%

Technical

SMA 503.220 (-8.0%)

SMA 2004.678 (-36.7%)

Beta1.26

S&P 52W Chg14.58%

Avg Vol (30d)922.37K

Avg Vol (10d)1.02M

Technical Indicators

RSI (14)43.5

MACD-0.0953

MACD Signal-0.1372

MACD Hist.+0.0419

BB Upper3.210 EUR

BB Middle2.931 EUR

BB Lower2.652 EUR

BB Width19.04%

ATR (14)0.1314 EUR

Vol Ratio (20d)0.65x